Since the mid-1950s the pharmaceutical industry has developed a number of chemicals, including phencyclidine, ketamine and related arylcyclohexylamines (PCE and TCP), dizocilpine (MK-801), N-allylnormetazocine [ NANM, (±)SKF-10,047], etoxadrol, dioxadrol and its enantiomers dexoxadrol and levoxadrol, which produce a constellation of unusual behavioral effects in animals and man. The compounds best studied in humans are phencyclidine and ketamine. They produce a remarkable dose-dependent dissociation of awareness. All of these substances are now known to be non-competitive antagonists of NMDA receptors of glutamic acid. They act in the NMDA receptor ion channel. One can conclude, on the basis of the effects observed with these agents, that glutamic acid and related excitatory amino acids are extremely important in the maintenance of human awareness.
Albin M.S., Bunegin L., Garcia C. (1990) Ketamine and postanesthetic emergence reactions . In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 17-25
2.
Berry S.C., Anis N.A., Lodge D. (1984) The effect of the dioxolanes on amino acid induced excitation in the mammalian spinal cord. Brain Res307: 85-90
3.
Brady K.T., Balster R.L., May E.L. (1982) Stereoisomers of N-allylnormetazocine: Phencyclidine-like behavioral effects in squirrel monkeys and rats. Science215: 178-180
4.
Burns R.S., Lerner S.E. (1981) The effects of phencyclidine in man: A review. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 449-470
5.
Carlsson M., Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease. Trends Neuropsychol13: 272-276
6.
Chen G. ( 1981) The neuropharmacology of phencyclidine. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 9-16
7.
Clineschmidt B.V., Martin G.E., Bunting P.R. (1982a) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res2: 123-134
8.
Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. (1982b) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res2: 135-145
9.
Clineschmidt B.V., Williams M., Witoslawski J.J., Bunting P.R., Risley E.A., Totaro J.A. (1982c) Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res2: 147-163
10.
Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S., Yelen D. (1959) Comparison of Sernyl with other drugs. I. Attention, motor function and proprioception. Arch Gen Psychiatr1: 651-656
11.
Corssen G. (1990) Historical aspects of ketamine-first clinical experience . In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 1-5
12.
Corssen G., Domino E.F. (1966) Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581 . Anesth Analg45: 29-40
13.
Domino E.F., Chodoff P., Corssen G. (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic in man. Clin Pharmacol Ther6: 279-291
14.
Domino E.F., Luby E.D. (1981) Abnormal mental states induced by phencyclidine as a model of schizophrenia. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives . NPP Books, Ann Arbor, pp. 401-418
15.
Domino E F, Kamenka J-M, eds (1988) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor
16.
Dundee J.W. (1990a) Early British experience with ketamine. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 7-10
17.
Dundee J.W. (1990b) The taming of ketamine. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 11-16
18.
Fauman M.A., Fauman B.J. (1981) Chronic phencyclidine (PCP) abuse: A psychiatric perspective. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 419-436
19.
Foster N.L., Giordani B., Mellow A., Aronson S., Berent S. (1991) Memory effects of low-dose ketamine in Alzheimer's disease. Neurology41: 214
20.
Frederickson E.L., Longnecker D.E., Allen G.W. (1976) Clinical investigation of a new intravenous anesthetic— etoxadrol hydrochloride (C1-1848:U-37862A). Anesth Analg Curr Res55: 335-339
21.
Greifenstein F.E., DeVault M., Yoshitake J., Gajewski J.E. (1958) A study of 1-arylcyclohexylamine for anesthesia . Anesth Analg37: 283-294
22.
Hampton R.Y., Medzihradsky F., Woods J.H., Dahlstrom P.J. (1982) Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sci30: 2147-2154
23.
Iversen L.L., Woodruff G.N., Kemp J.A., Foster A.C., Gill R., Wong E H F (1988) Pharmacology and neuroprotective effects of the NMDA antagonist MK-801. In Domino E F, J-M Kamenka (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp. 757-766
24.
Javitt DC, Zukin S.R. (1991) Recent advances in the phencyclidine model of schizophrenia . Am J Psychiatr148: 1301-1308
25.
Jasinski D.R., Martin W.R., Sappira J.D. (1968) Progress report on the dependence-reducing properties of GPA-1657, profadol hydrochloride (CI-572), propiram fumarate (BAY-4503) and dexoxadrol. Reported to the 30th Meeting, Committee on Problems of Drug Dependence, National Research Council , Indianapolis IN
26.
Johnstone M., Evans V., Baigel J.R. (1959) Sernyl (CI-395) in clinical anesthesia. Br J Anaesth31: 433-439
27.
Kamenka J-M, Domino E F, eds (1992) Multiple sigma and PCP ligands: mechanisms for neuromodulation and neuroprotection? NPP Books, Ann Arbor
28.
Keats A.S., Telford J. (1964) Narcotic antagonists as analgesics. In Gould R F (ed.), Clinical aspects, series 45: molecular modification in drug design, advances in chemistry. American Chemical Society, Washington, pp. 170-176
29.
Kemp J.A., Priestley T., Woodruff G.N (1986) MK-801, a novel orally-active anticonvulsant, is a potent non-competitive N-methyl-D-aspartate receptor antagonist. Br J Pharmacol Proc Suppl89: 535P
30.
Koek W., Woods J.H. (1988a) Assessing directly observable behavioral effects of phencyclidine (PCP)-like drugs in pigeons, in rats, and in rhesus monkeys . In Domino E F, Kamenka J-M (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp. 493-509
31.
Koek W., Woods J.H. (1988b) Correlations between phencyclidine-like activity and N-methyl-D-aspartate antagonism: Behavioral effects. In Domino E F, Kamenka J-M (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp.357-372
32.
Largent BL, Gundlach AL, Schneider SH (1986) Pharmacological and autoradiographical discrimination of sigma and phencyclidine receptor binding sites in brain with (+) [ 3H] SKF-10,047, (+) [3H] 3-PPP, and [3H] TCP. J Pharmacol Exp Ther238: 739-748
33.
Lasagna L., Pearson J.W. (1965) Analgesic and psychotomimetic properties of dexoxadrol . Proc Soc Exp Biol Med118: 352-354
34.
Lear E., Suntay R., Pallin IN, Chiron A.E. (1959) Cyclohexamine (CI-400): A new intravenous agent . Anesthesiology20: 330-335
35.
Lodge D., Anis N.A., Berry S.C., Burton N.R. (1983) Arylcyclohexylamines selectively reduce excitation of mammalian neurones by aspartate-like amino acids. In Kamenka J-M, Domino E F, Geneste P (eds), Phencyclydine and related arylcylohexylamines: present and future applications. NPP Books, Ann Arbor, pp. 595-616
36.
Luby E.D. (1981) Phencyclidine revisited. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor , pp. 25-30
37.
Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. (1959) Study of a new schizophrenomimetic drug— Sernyl. Arch Neurol Psychiatr81: 363-369
38.
Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. (1962) Model psychoses and schizophrenia. Am J Psychiatr119: 61-67
39.
Maddox V.H. (1981) The historical development of phencyclidine. In Domino E F (ed.) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 1-8
40.
Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. (1976) The effects of morphine and nalorphinelike drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther197: 517-532
41.
McCarthy D.A. (1981) History of the development of cataleptoid anesthetics of the phencyclidine type. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 17-23
42.
Meyer J.S., Greifenstein F., DeVault M. (1959) A new drug causing symptoms of sensory deprivation: Neurological, electroencephalographic and pharmacologic effects of Sernyl . J Nerve Ment Dis129: 54-61
43.
Musacchio J.M. (1990) The psychotomimetic effects of opiates and the σ receptor. Neuropsychopharmacology3: 191-200
44.
Øye I., Hustveit O., Maurset A., Ratti Mobert E., Paulsen O., Skoglund L.A. (1991) The chiral forms of ketamine as probes for NMDA receptor functions in human. In Kameyama T , Nabeshima T, Domino E F (eds), NMDA receptor related agents: biochemistry, pharmacology and behavior. NPP Books, Ann Arbor, pp. 381-390
45.
Reimherr F.W., Wood D.R., Wender P.H. (1986) The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull22: 237-242
46.
Scholler K.L., Thies H., Wiemers K. (1960) Die Allgemeinanaesthesie mit Cyclohexylaminodrivaten, klinische Beobachtungen und elektrencephalographische Untersuchungen (General anesthesia with cyclohexylamine derivatives, clinical observations and electroencephalographic studies). Der Anaesthesist9: 163-169
47.
Simopoulos A.M., Pinto A., Babikow P.W., Curland A., Savage C. (1970) Psychotomimetic properties and therapeutic potentials of dexoxadrol in convalescing alcoholics. Disease Nerv Syst31: 203-207
48.
Troupin A.S., Mendius J.R., Cheng F., Risinger M. W (1986) MK-801. In Meldrum B S, Porter R J (eds), New anticonvulsant drugs. John Libbey, London, pp. 191-201
49.
Vaupel D.B. (1983) Naltrexone fails to antagonize the σ effects of PCP and SKF-10,047 in the dog. Eur J Pharmacol92: 269-274
50.
Wilson R.D., Traber D.L., Barratt E., Creson D., Schmitt R., Allen C.R. (1970) Evaluation of CL-1848C: A new dissociative anesthetic in normal human volunteers. Anesth Analg Curr Res49: 236-241
51.
Wilson R.D., Allen C.R., Creson D., Schmitt R., Barratt E., Traber D.L. (1973) Operant behavior and neurophysiological observations of normal human volunteers receiving CL-1848C, a new dissociative anesthetic . Tex Rep Biol Med31: 239-248
52.
Wong E H F, Kemp J.A., Priestley T., Night A.R., Woodruff G.N., Iversen L.L. (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA83: 7104-7108
